-

Soundbite Medical to Participate in Oppenheimer's 32nd Annual Healthcare Virtual Investor Conference

MONTREAL--(BUSINESS WIRE)--Soundbite Medical Solutions Inc. (SBMS), a medical device company leveraging its proprietary shock wave technology for the interventional treatment of calcific occlusive peripheral and coronary arterial diseases, today announced that members of its senior management team will participate in the 32nd Annual Oppenheimer Healthcare Conference, March 15-17, 2022.

Oppenheimer 32nd Annual Healthcare Conference
Date: March 17, 2022
Time: 2:00 p.m. Eastern Time

During the virtual event, the Company will also be conducting 1×1 virtual investor meetings.

A live webcast of the presentation will be available starting Thursday, March 17, 2022 at 2:00 p.m. Eastern Time at:

https://wsw.com/webcast/oppenheimer20/sdbt/2769606.

A replay of the webcast will be available for 90 days using the above link, as well as on the company website www.soundbitemedical.com.

About Soundbite Medical Solutions

Soundbite is a privately-held medical device company uniquely dedicated to developing meaningful solutions for the interventional treatment of calcific peripheral and coronary arterial diseases. Soundbite has developed and deployed a proprietary method to produce and safely deliver shock waves to calcified lesions using an array of devices to improve and transform the standard of care for treatment of patients suffering from calcified and occlusive cardiovascular disease. www.soundbitemedical.com

For information on Soundbite Medical Solutions, please contact Ashkan Haghighat, PhD (ashkan.haghighat@soundbitemedical.com)

Forward-Looking Statements This press release contains forward-looking statements and forward- looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond SoundBite Medical Solutions Inc.’s control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward looking statements. Forward- looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances.

Contacts

Soundbite Medical Solutions Inc.


Release Versions

Contacts

More News From Soundbite Medical Solutions Inc.

Soundbite Medical Solutions Announces Issuance of Two New U.S. Patent Further Expanding Coverage of its Shock Wave Technology

MONTREAL--(BUSINESS WIRE)--Soundbite Medical Solutions Inc. (SBMS), a medical device company leveraging its proprietary shock wave technology for the interventional treatment of calcific occlusive peripheral and coronary arterial diseases, today announced that the United States Patent and Trademark Office has issued two additional US patents. Patent No. 11,419,619, entitled “Method and system for treating lesions” is directed to a medical procedure exploiting the use of externally-generated sho...

Soundbite Medical Enters Into A License Agreement With VFLO Medical To Bring Its Products To Greater China

MONTREAL--(BUSINESS WIRE)--Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific occlusive peripheral and coronary arterial diseases, today announced that it has entered into an exclusive license agreement with VFLO Medical (VFLO). Pursuant to the agreement, Soundbite has granted VFLO an exclusive license for certain proprietary products including its SoundBite Crossing System and the Active Microcatheter...

Soundbite Medical Announces Issuance Of A Fifth U.S. Patent Covering Novel Active Balloon Devices Intended For Plaque Modification Of Calcified Arteries

MONTREAL--(BUSINESS WIRE)--Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific occlusive peripheral and coronary arterial diseases, today announced that the United States Patent and Trademark Office has issued US patent No. 11,179,169, entitled “Device for delivering mechanical waves through a balloon catheter”. The patent is directed to a device for delivering high amplitude broadband mechanical pulses...
Back to Newsroom